evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 2 reviews · Stroke

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 2 · 28.6%Moderate 2 · 28.6%High 0 · 0%

Standard‐dose VKA plus single antiplatelet agent vs one antiplatelet agent

Major bleeding (minor cerebral hemorrhage) · people with antiphospholipid syndrome, with previous stroke

It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes major bleeding (minor cerebral hemorrhage) compared with single antiplatelet agent (very low certainty).

1 finding from 1 review

Standard‐dose VKA plus single antiplatelet agent vs one antiplatelet agent

Any bleeding that does not meet criteria for major bleeding ‐ Gastrointestinal bleeding (no definition) · people with antiphospholipid syndrome, with previous stroke

It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes any bleeding that does not meet criteria for major bleeding ‐… compared with single antiplatelet agent (very low certainty).

1 finding from 1 review

Standard‐dose VKA plus single antiplatelet agent vs vitamin K antagonist (VKA)

Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

Standard‐dose VKA plus single antiplatelet agent showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).

1 finding from 1 review

NOAC (rivaroxaban) vs vitamin K antagonist (VKA)

Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

NOAC (rivaroxaban) showed no clear difference in major bleeding compared with standard‐dose VKA (moderate certainty).

1 finding from 1 review

Anticoagulant drugs: VKA high dose vs vitamin K antagonist (VKA)

Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

High‐dose VKA showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).

1 finding from 1 review

NOAC (rivaroxaban) vs vitamin K antagonist (VKA)

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

NOAC (rivaroxaban) showed no clear difference in clinically relevant non‐major bleeding compared with standard‐dose VKA (moderate certainty).

1 finding from 1 review